Last --
Change Today 0.00 / 0.00%
Volume 0.0
JNJ On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
Sao Paulo
Bogota
All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Open
--
Previous Close
$189,300
Day High
--
Day Low
--
52 Week High
08/1/14 - $134,218
52 Week Low
08/1/14 - $134,218
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
2.8B
EX-Date
11/21/14
P/E TM
--
Dividend
$2.80
Dividend Yield
2.80%
Current Stock Chart for JOHNSON & JOHNSON (JNJ)

johnson & johnson (JNJ) Details

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women’s health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON’S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

126,000 Employees
Last Reported Date: 10/14/14
Founded in 1885

johnson & johnson (JNJ) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.5M
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $842.3K
Group Worldwide Chairman and Member of Execut...
Total Annual Compensation: $2.7M
Worldwide Chairman of Pharmaceuticals, Chief ...
Total Annual Compensation: $952.9K
Vice President, General Counsel and Member of...
Total Annual Compensation: $542.3K
Compensation as of Fiscal Year 2013.

johnson & johnson (JNJ) Key Developments

Johnson & Johnson Is Reported To Sell Two Brands In India For INR 3 Billion

Johnson & Johnson (NYSE:JNJ) is close to selling two of its brands, Savlon antiseptic soap and liquids, and Shower to Shower talcum powder, in India for over INR 3 billion. J&J India's non-core divestment has attracted the attention of multiple suitors, sources who did not want to be named as the sale process is currently under way, told TOI. Wipro Consumer Care and Lighting Ltd. Wipro Consumer Care and Lighting Ltd., Emami Limited (BSE:531162) and Dabur India Ltd. (BSE:500096) are among the bidders who have looked at the deal. The transaction involves selling brand rights and technical know-how, sources said. When contacted by TOI, a J&J India spokesperson said J&J would not comment on speculation. Wipro declined to comment, while Emami could not be reached for immediate comments, reported TOI.

Johnson & Johnson Declares Cash Dividend for the Fourth Quarter of 2014, Payable on December 9, 2014

Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2014 of $0.70 per share on the company's common stock. The dividend is payable on December 9, 2014 to shareholders of record at the close of business on November 25, 2014. The ex-dividend date is November 21, 2014.

Johnson & Johnson Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months of 2014; Revises Earnings Guidance for the Full Year 2014

Johnson & Johnson announced unaudited consolidated earnings results for the third quarter and nine months of 2014. For the quarter, the company reported sales to customers of $18,467 million against $17,575 million a year ago. Earnings before provision for taxes on income were $6,810 million against $3,667 million a year ago. Net earnings were $4,749 million or $1.66 per diluted share against $2,982 million or $1.04 per diluted share a year ago. Earnings before provision for taxes on income - as adjusted were $5,660 million against $4,831 million a year ago. Net earnings - as adjusted were $4,292 million or $1.50 per diluted share against $3,919 million or $1.36 per diluted share a year ago. For the nine months, the company reported sales to customers of $56,077 million against $52,957 million a year ago. Earnings before provision for taxes on income were $17,860 million against $12,721 million a year ago. Net earnings were $13,802 million or $4.81 per diluted share against $10,312 million or $3.58 per diluted share a year ago. Earnings before provision for taxes on income - as adjusted were $17,270 million against $15,260 million a year ago. Net earnings - as adjusted were $13,493 million or $4.70 per diluted share against $12,315 million or $4.28 per diluted share a year ago. The company increased its earnings guidance for full-year 2014 to $5.92 - $5.97 per share. The company's guidance excludes the impact of special items.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:CB $189,300.00 COP 0.00

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
International Business Machines Corp $163.23 USD -5.87
Novartis AG SFr.83.70 CHF +0.15
Pfizer Inc $28.28 USD +0.35
Roche Holding AG SFr.275.40 CHF +0.70
Procter & Gamble Co/The $84.61 USD +0.43
View Industry Companies
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
Price/Earnings 16.4x
Price/Sales 3.8x
Price/Book 3.6x
Price/Cash Flow 16.2x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit www.jnj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.